Search Result

Results for "

seizures

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adenosine Kinase (1) Adenosine Receptor (1) Amino Acid Derivatives (2) Antibiotic (1) Apoptosis (4) Autophagy (9) Bacterial (2) Beta-secretase (1) Calcium Channel (4) Carbonic Anhydrase (5) Caspase (2) Cuproptosis (2) Drug Metabolite (5) EAAT (1) EGFR (2) Endogenous Metabolite (7) Fungal (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (9) Glutaminase (1) GlyT (2) Histamine Receptor (3) iGluR (8) Isotope-Labeled Compounds (4) mAChR (3) MAGL (1) mGluR (3) Neuropeptide Y Receptor (1) NKCC (2) Opioid Receptor (2) P-glycoprotein (1) PKA (1) Potassium Channel (1) ROCK (1) Sigma Receptor (1) Sodium Channel (17) Somatostatin Receptor (2) TRP Channel (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (9) Endocrinology (2) Infection (2) Inflammation/Immunology (11) Metabolic Disease (6) Neurological Disease (97)

By Targets:

5-HT Receptor (6)

Adenosine Kinase (1)

Adenosine Receptor (1)

Amino Acid Derivatives (2)

Antibiotic (1)

Apoptosis (4)

Autophagy (9)

Bacterial (2)

Beta-secretase (1)

Calcium Channel (4)

Carbonic Anhydrase (5)

Caspase (2)

Cuproptosis (2)

Drug Metabolite (5)

EAAT (1)

EGFR (2)

Endogenous Metabolite (7)

Fungal (1)

G protein-coupled Bile Acid Receptor 1 (1)

GABA Receptor (9)

Glutaminase (1)

GlyT (2)

Histamine Receptor (3)

iGluR (8)

Isotope-Labeled Compounds (4)

mAChR (3)

MAGL (1)

mGluR (3)

Neuropeptide Y Receptor (1)

NKCC (2)

Opioid Receptor (2)

P-glycoprotein (1)

PKA (1)

Potassium Channel (1)

ROCK (1)

Sigma Receptor (1)

Sodium Channel (17)

Somatostatin Receptor (2)

TRP Channel (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (9)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (11)

Metabolic Disease (6)

Neurological Disease (97)

113

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123671

CYM2503	Neuropeptide Y Receptor	Neurological Disease
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .

HY-111177

Pheneturide Ethylphenacemide; M 551	Others	Neurological Disease
Pheneturide (Ethylphenacemide, M 551), a decarboxylation product of Phenobarbital, can be used to prevent psychomotor seizures .

HY-12503

CFM-2 1 Publications Verification	iGluR	Neurological Disease Cancer
CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .

HY-B0495

Lamotrigine 5+ Cited Publications LTG; BW430C	Sodium Channel Autophagy	Neurological Disease Cancer
Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-131204

CZL80	Caspase	Neurological Disease
CZL80, a brain-penetrable caspase-1 inhibitor with an IC₅₀ of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility .

HY-153068

CZL55	Caspase	Inflammation/Immunology
CZL55 is a caspase-1 inhibitor with an IC₅₀ value of 24 nM. CZL55 can be used for the research of febrile seizures (FS) .

HY-W013378

Carbamazepine 10,11-epoxide	Endogenous Metabolite	Neurological Disease
Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-100922

N-Acetylglycyl-D-glutamic acid	Others	Neurological Disease
N-Acetylglycyl-D-glutamic acid is a peptide with excitatory effect. N-Acetylglycyl-D-glutamic acid induces seizures in mice .

HY-B0495A

Lamotrigine hydrate LTG hydrate; BW430C hydrate	Sodium Channel Autophagy	Neurological Disease
Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al .

HY-W751152

α,β-Thujone	Others	Cancer
α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-111177R

Pheneturide (Standard)	Others	Neurological Disease
Pheneturide (Standard) is the analytical standard of Pheneturide. This product is intended for research and analytical applications. Pheneturide (Ethylphenacemide, M 551), a decarboxylation product of Phenobarbital, can be used to prevent psychomotor seizures .

HY-130325

α-Guanidinoglutaric acid	Others	Neurological Disease
α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .

HY-B0495S6

Lamotrigine-13C2,15N2,d3 LTG-13C2,15N2,d3; BW430C-13C2,15N2,d3	Autophagy Sodium Channel Isotope-Labeled Compounds	Neurological Disease Cancer
Lamotrigine- ¹³C₂, ¹⁵N₂,d₃ is ¹⁵N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-B1657

Fosphenytoin	Others	Neurological Disease
Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .

HY-B0495R

Lamotrigine (Standard) 5+ Cited Publications	Sodium Channel	Neurological Disease
Lamotrigine (Standard) is the analytical standard of Lamotrigine. This product is intended for research and analytical applications. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-118467

Benzolamide CL11366	Carbonic Anhydrase	Neurological Disease
Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with K_is of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a K_i of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .

HY-W751152R

α,β-Thujone (Standard)	Others	Cancer
α,β-Thujone (Standard) is the analytical standard of α,β-Thujone. This product is intended for research and analytical applications. α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-W013378R

Carbamazepine 10,11-epoxide (Standard)	Endogenous Metabolite	Neurological Disease
Carbamazepine 10,11-epoxide (Standard) is the analytical standard of Carbamazepine 10,11-epoxide. This product is intended for research and analytical applications. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-B1730

Phensuximide 1 Publications Verification	Others	Neurological Disease Metabolic Disease
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .

HY-106316

CGS 20625	GABA Receptor	Neurological Disease
CGS 20625 is a potent, selective and orally active partial agonist for the central benzodiazepine receptor. CGS 20625 inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors with an IC₅₀ of 1.3 nM. CGS 20625 can be used for the research of pentylenetetrazol-induced seizures .

HY-118696

MGAT2-IN-5	GABA Receptor	Neurological Disease
MGAT2-IN-5 (Compound 17b) is a selective inhibitor for mouse GABA transit protection subsidity 2 (mGAT2) with an IC₅₀ of 45 μM. MGAT2-IN-5 exhibits anticonvulsive efficacy in audiogenic seizure (AGS) susceptible frings mouse model with an ED₅₀ of 20.4 mg/kg .

HY-A0092

Trimethadione 3,5,5,-Trimethyloxazolidine-2,4-dione	Calcium Channel	Neurological Disease
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .

HY-148327

AK-IN-1	Adenosine Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .

HY-139382

2-(Isopentylamino)naphthalene-1,4-dione	Others	Neurological Disease
2-(Isopentylamino)naphthalene-1,4-dione (compound 3d), a Vitamin K (HY-B2172) analogue, shows protection in Pentylenetetrazole (PTZ)-induced seizure model. 2-(Isopentylamino)naphthalene-1,4-dione significantly increases ATP levels in zebrafish as well as HT-22 cells. 2-(Isopentylamino)naphthalene-1,4-dione shows excellent permeability into the brain .

HY-108497

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective somatostatin sst4 receptor agonist with a K_i of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-108497A

L-803087 TFA	Somatostatin Receptor	Neurological Disease Cancer
L-803087 TFA is a potent and selective somatostatin sst4 receptor agonist with a K_i of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-A0092R

Trimethadione (Standard)	Calcium Channel	Neurological Disease
Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .

HY-12596

JNJ-26489112	Calcium Channel Sodium Channel Potassium Channel	Neurological Disease
JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na ⁺ channels and N-type Ca ²⁺ channels, and is effective as a K ⁺ channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC₅₀=35 μM) and CA-I (18 μM) .

HY-123934

VU6007477	P-glycoprotein	Neurological Disease
VU6007477 is a brain-penetrant, selective M1 positive allosteric modulator (PAM) with an EC₅₀ value of 230 nM. VU6007477 is also a human P-glycoprotein (P-gp) substrate with moderate permeability. VU6007477 displays improved central nervous system (CNS) penetration over the hydroxylated congeners. VU6007477 a pyranyl amide derivative, which is promising for research of robust cholinergic seizure activity .

HY-100840

(S)-4C3HPG (S)-4-Carboxy-3-hydroxyphenylglycine	mGluR	Neurological Disease
(S)-4C3HPG ((S)-4-Carboxy-3-hydroxyphenylglycine) is an antagonist of metabotropic glutamate receptor 1a (mGluR 1a) and an agonist of GluR2. (S)-4C3HPG has the anticonvulsant activity and protects against audiogenic seizures in DBA/2 mice .

HY-Y0378

D-Leucine (R)-Leucine	Endogenous Metabolite	Neurological Disease
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-B0300

Penicillamine 2 Publications Verification D-(-)-Penicillamine	Cuproptosis Drug Metabolite	Inflammation/Immunology Cancer
Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine reduces free copper and reduces oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-100839

(RS)-(Tetrazol-5-yl)glycine D,L-(tetrazol-5-yl)glycine; LY 285265	iGluR	Neurological Disease
(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist . (RS)-(Tetrazol-5-yl)glycine has EC₅₀s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively . (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice .

HY-B0124

Zonisamide AD 810; CI 912	Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124A

Zonisamide sodium AD 810 sodium; CI 912 sodium	Carbonic Anhydrase Apoptosis	Cardiovascular Disease Neurological Disease
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-B0300R

Penicillamine (Standard)	Cuproptosis Drug Metabolite	Inflammation/Immunology Cancer
Penicillamine (Standard) is the analytical standard of Penicillamine. This product is intended for research and analytical applications. Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine reduces free copper and reduces oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-B0124R

Zonisamide (Standard)	Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-Y0378R

D-Leucine (Standard)	Endogenous Metabolite	Neurological Disease
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-114542

LY 201409	Others	Others
LY 201409 is a compound with anticonvulsant activity that can antagonize maximal electroconvulsive-induced epileptic seizures, has mixed effects on epileptic seizures induced by a variety of chemical convulsants, and can also affect the behavior and sleep of mice.

HY-B1692

L-Methionine-DL-sulfoximine 1 Publications Verification MSX; MSO	Glutaminase	Neurological Disease
L-Methionine-DL-sulfoximine (MSX; MSO), a highly specific and irreversible inhibitor of Glutamine synthetase (GS), is also a potent convulsant which metabolically and morphologically primarily affects astroglia. L-Methionine-DL-sulfoximine has been employed to inhibit the Gln-dependent ammonia-stimulated neuronal toxicity in vitro, potentiating Gln deficit-dependent depression. L-Methionine-DL-sulfoximine tremendously increases the rate of release of fixed nitrogen in cyanobacteria. L-Methionine-DL-sulfoximine is a promising candidate for research in biofertilizers and convulsive seizures (CS) .

HY-114703

Eslicarbazepine 1 Publications Verification BIA 2-194	Beta-secretase Sodium Channel	Neurological Disease
Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-156533A

5-HT2 agonist-1 free base	5-HT Receptor	Neurological Disease Inflammation/Immunology Cancer
5-HT2 agonist-1 (Compound 24) free base is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC₅₀s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .

HY-156533

5-HT2 agonist-1	5-HT Receptor	Cancer
5-HT2 agonist-1 (Compound 24) is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC₅₀s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .

HY-156534

5-HT2A&5-HT2C agonist-1	5-HT Receptor	Neurological Disease Inflammation/Immunology Cancer
5-HT2A&5-HT2C agonist-1 (Example 2) is a 5-HT2A & 5-HT2C agonist, with IC₅₀s of 196 nM and 0.9 nM respectively. 5-HT2A&5-HT2C agonist-1 can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a delta-opioid receptor antagonist and can be used for seizure research.

HY-W013378S

Carbamazepine 10,11 epoxide-d2	Endogenous Metabolite Isotope-Labeled Compounds	Others
Carbamazepine 10,11 epoxide-d₂ is the deuterium labeled Carbamazepine 10,11 epoxide[1]. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[2].

HY-B1606

Chlorothymol Chlorthymol; 6-Chlorothymol	GABA Receptor Bacterial	Neurological Disease Inflammation/Immunology
Chlorothymol (Chlorthymol) is a potent GABA_A receptor subunit LGC-37 positive modulator. Chlorothymol is an effective anticonvulsant. Chlorothymol is protective in several mouse seizure assays, including the 6-Hz 44-mA model of pharmacoresistant seizures. Chlorothymol possess GABAergic, membrane-modifying, antioxidant and topical antiseptic properties .

HY-145671

5-(3-hydroxyphenyl)-5-phenylhydantoin	Drug Metabolite	Others
5-(3-hydroxyphenyl)-5-phenylhydantoin, is a metabolite of anti-seizure agent Phenytoin .

HY-122489

DL-Laudanosine	Drug Metabolite	Neurological Disease
DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

Cat. No.	Product Name	Target	Research Area

HY-W023493

DL-Allylglycine 2-Aminopent-4-enoic acid	Amino Acid Derivatives	Neurological Disease
DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .

HY-138903

L-Homocysteic acid L-HCA	iGluR	Neurological Disease
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC₅₀: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders .

HY-P1237

C-Type Natriuretic Peptide (CNP) (1-22), human 1 Publications Verification	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-P1237A

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 1 Publications Verification	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-W002299

Boc-D-Leucine monohydrate Boc-D-Leu-OH hydrate	Amino Acid Derivatives	Neurological Disease
Boc-D-Leucine monohydrate (Boc-D-Leu-OH hydrate) is an N-Boc-protected form of D-Leucine. D-Leucine is an unnatural isomer of L-Leucine that acts as an auto-inhibitor of lactic streptococci. D-Leucine shows potent anti-seizure effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013378

Carbamazepine 10,11-epoxide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-Y0378

D-Leucine (R)-Leucine	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-B0300

Penicillamine 2 Publications Verification D-(-)-Penicillamine	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Inflammation/Immunology Disease Research Fields	Cuproptosis Drug Metabolite
Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine reduces free copper and reduces oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-122489

DL-Laudanosine	Alkaloids Microorganisms Animals Source classification Isoquinoline Alkaloids	Drug Metabolite
DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

HY-N2309

Kainic acid 5+ Cited Publications	Alkaloids Structural Classification other families Pyrrole Alkaloids Neurological Disease Classification of Application Fields Source classification Plants Disease Research Fields Biological Pesticide Research Agricultural Research	EAAT
Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures .

HY-W751152

α,β-Thujone	Structural Classification Terpenoids Source classification Artemisia austriaca Jacq. Plants Compositae	Others
α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-W751152R

α,β-Thujone (Standard)	Structural Classification Terpenoids Source classification Artemisia austriaca Jacq. Plants Compositae	Others
α,β-Thujone (Standard) is the analytical standard of α,β-Thujone. This product is intended for research and analytical applications. α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-W013378R

Carbamazepine 10,11-epoxide (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite
Carbamazepine 10,11-epoxide (Standard) is the analytical standard of Carbamazepine 10,11-epoxide. This product is intended for research and analytical applications. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-B0300R

Penicillamine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Cuproptosis Drug Metabolite
Penicillamine (Standard) is the analytical standard of Penicillamine. This product is intended for research and analytical applications. Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine reduces free copper and reduces oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-Y0378R

D-Leucine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-122489R

DL-Laudanosine (Standard)	Alkaloids Structural Classification Microorganisms Animals Source classification Isoquinoline Alkaloids	Drug Metabolite
DL-Laudanosine (Standard) is the analytical standard of DL-Laudanosine. This product is intended for research and analytical applications. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

HY-N0219

Bicuculline Maximum Cited Publications 21 Publications Verification (+)-Bicuculline; d-Bicuculline	Alkaloids Structural Classification Source classification Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae	GABA Receptor
Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABA_A receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca ²⁺ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-122489A

(S)-Laudanosine	Structural Classification Alkaloids Microorganisms Source classification Isoquinoline Alkaloids	Others
(S)-Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC₅₀ value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (K_i = 2.7 μM) .

HY-N0219R

Bicuculline (Standard)	Alkaloids Structural Classification Source classification Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae	GABA Receptor
Bicuculline (Standard) is the analytical standard of Bicuculline. This product is intended for research and analytical applications. Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

Cat. No.	Product Name	Chemical Structure

HY-Y0378S

D-Leucine-d10
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].

HY-B0495S5

Lamotrigine-d3
Lamotrigine-d3 is the deuterium labeled Lamotrigine[1]. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[2][3].

HY-B0495S6

Lamotrigine-13C2,15N2,d3

Lamotrigine- ¹³C₂, ¹⁵N₂,d₃ is ¹⁵N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-W013378S

Carbamazepine 10,11 epoxide-d2
Carbamazepine 10,11 epoxide-d₂ is the deuterium labeled Carbamazepine 10,11 epoxide[1]. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[2].

HY-W013378S2

Carbamazepine 10,11-epoxide-13C,d2
Carbamazepine 10,11-epoxide- ¹³C,d₂ is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a ¹³C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[1][2].

HY-B0495S4

Lamotrigine-13C3
Lamotrigine- ¹³C₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].

HY-B0495S1

Lamotrigine-13C,d3
Lamotrigine- ¹³C,d₃ is the ¹³C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].

HY-B0495S

Lamotrigine-13C3,d3
Lamotrigine- ¹³C₃,d₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].

HY-B0495S3

Lamotrigine-13C2,15N
Lamotrigine-13C2,15N is the 13C and 15N labeled Lamotrigine[1]. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks